ABBV vs GILD
By Alex · Tickerpine
AbbVie Inc. vs Gilead Sciences, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | GILD |
|---|---|---|
| Price | $253.35 | $127.88 |
| Market cap | $447.62B | $158.77B |
| P/E ratio | 123.6 | 17.4 |
| ROE | — | 43.36% |
| Profit margin | 5.79% | 30.99% |
| Revenue growth | 12.40% | 4.40% |
| Dividend yield | 2.73% | 2.56% |
| Beta | 0.31 | 0.33 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs GILD in plain English
- ABBV is the bigger company — about 2.8× the market cap of GILD.
- GILD is cheaper on earnings (P/E 17.4 vs 123.6).
- ABBV is growing revenue faster (12% vs 4%).
- ABBV has the higher dividend yield (2.73% vs 2.56%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
GILD return calculator
See what $1,000 in Gilead Sciences, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.